Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data. Garry JD, Brittain EL. Circulation 2026;153:980-982.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Garry JD, Brittain EL. Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data. Circulation 2026;153:980-982.
PMID: 41911355